22ND CENTURY GROUP INC

XXII stock represents shares of 22nd Century Group, Inc., a U.S.-based company focused on tobacco harm reduction and plant biotechnology. It trades on the Nasdaq under the ticker XXII. The stock gives investors exposure to a small-cap consumer and biotechnology business whose products include reduced-nicotine tobacco and hemp/cannabis-related plant technologies. Investors should review XXII's latest filings and the current data on this page for up-to-date details.

XXII's share price can respond to company-specific developments such as regulatory decisions, product trials, earnings reports, financing activities, and shifts in strategy. Broader influences include tobacco and cannabis regulation, commodity input costs, interest rates, and small-cap market sentiment. Because XXII is a smaller company, news flow and changes in liquidity can create sharp price movements. Monitoring official filings and the latest XXII quote helps put these factors in context.

Valuation for XXII is less straightforward than for a mature, profitable company. Investors may compare enterprise value, price-to-sales, and book value against peers in tobacco and plant biotechnology, but many traditional metrics such as P/E are not meaningful when earnings are negative. Reviewing balance sheet quality, cash burn, and growth prospects is often more useful. Check the valuation data displayed on this XXII page for current figures.

XXII can potentially be traded in pre-market and after-hours sessions on U.S. exchanges, though liquidity is typically much lower than during regular trading hours. Extended-hours trades may execute at wider spreads and with greater price volatility because fewer participants are active. Not all brokers offer this access, and order types may be restricted. Investors should confirm their broker's extended-hours rules and the latest XXII quote before placing orders.

Begin with XXII's quarterly and annual filings, which include the income statement, balance sheet, and cash flow statement. Track revenue trends, gross margin, operating expenses, net loss, and cash used in operations. For a company like XXII, cash position and financing needs often matter as much as earnings. Comparing multiple periods helps reveal direction, but the most current figures should be taken from the XXII data on this page.

Risks include regulatory uncertainty around tobacco and cannabis products, possible delays or failures in product commercialization, ongoing losses and cash needs, and potential shareholder dilution from future financing. As a small-cap stock, XXII may also see low liquidity and high volatility. Competitive pressure from larger tobacco and consumer companies is another consideration. These risks should be weighed alongside the company's strategy and current disclosures.